27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the individual 30 mg (by 34.6%) and 50 mg (by 38.5%) blarcamesine groups vs. placebo on the prespecified primary cognitive endpoint ADAS-Cog13. 5 key findings →
Design: open-label trial Participants: 338 Evidence: high
Full summary, score breakdown and related studies → Original source
These results provide further support for behavioral interventions for persons with MCI. 4 key findings →
Participants: 272 Evidence: high
Full summary, score breakdown and related studies → Original source
Efficacy, safety, biomarker, and PK profiles of aducanumab were consistent between the Japanese subgroup and the overall population. 5 key findings →
Design: clinical trial Participants: 121 Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, the study drug was well tolerated. 5 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Robust concordance between CSF biomarkers and amyloid PET visual status was observed (for Aβ42/Aβ40, AUC: 0.90; 95% CI: 0.83-0.97; p < 0.0001), confirming CSF biomarkers as a reliable alternative to amyloid PET in these studies. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
Between March 1, 2016, and March 12, 2020, 383 patients were enrolled and randomly assigned to the intervention or control group. 5 key findings →
Design: randomized controlled trial Participants: 383 Evidence: high
Full summary, score breakdown and related studies → Original source
The interventions were positively perceived, with 72.0% finding the consultation informative and 69.2% considering the app useful. 5 key findings →
Design: randomized controlled trial Participants: 188 Evidence: high
Full summary, score breakdown and related studies → Original source
Targeting of tau pathology has long been proposed as a potential therapeutic strategy for Alzheimer's disease (AD). 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
Thirty-three randomized controlled trials were identified evaluating 15,971 participants (9,103 (57%) female). 5 key findings →
Participants: 15,971 Evidence: high
Full summary, score breakdown and related studies → Original source
42 participants completed the study (NR = 22, placebo = 20). 5 key findings →
Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source
The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001), greater amyloid deposition (β = 0.48, p = 0.001), 2-year decline in hippocampus (β = -0.27, p = 0.01), total gray matter volume (β = -0.25, p = 0.01), and cortical thickness (β = -0.28, p = 0.003). 5 key findings →
Participants: 126 Evidence: high
Full summary, score breakdown and related studies → Original source
Adults aged 65+ are at highest risk for severe COVID-19 outcomes, and prior to the distribution of vaccines in the U.S., were strongly advised to quarantine at home to reduce risk of infection. 3 key findings →
Design: randomized controlled trial Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source
Of 285 participants randomized (suvorexant, N = 142; placebo, N = 143), 277 (97%) completed the trial (suvorexant, N = 136; placebo, N = 141). 4 key findings →
Participants: 142 Evidence: high
Full summary, score breakdown and related studies → Original source
In a cross-sectional analysis of 26 individuals, bifrontal cortical FDG hypometabolism was associated with worse Clinical Dementia Rating (CDR) plus National Alzheimer's Coordinating Center frontotemporal lobar degeneration sum of boxes score (b = -3.6 × 10-2 standardized uptake value ratio [SUVR] units/CDR units; 95% CI, -4.9 × 10-2 to -2.2 × 10-2; P < .001), high cerebrospinal fluid NfL (b = -9.2 × 10-5 SUVR units/pg NfL/mL; 95% CI, -1.3 × 10-4 to -5.6 × 10-5; P < .001), and high CSF t-tau (-7.2 × 10-4 SUVR units/pg t-tau/mL; 95% CI, -1.4 × 10-3 to -9.5 × 10-5; P = .03). 2 key findings →
Design: cross-sectional Participants: 27 Evidence: high
Full summary, score breakdown and related studies → Original source
ARIA is an adverse event associated with donanemab treatment that requires safety monitoring. 4 key findings →
Design: phase-3-trial Participants: 3,030 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 3285 included participants, the mean (SD) age was 70.4 (7.45) years; 1706 participants (52%) were female, 2661 (81%) had mild cognitive impairment due to Alzheimer disease, and 1777 (54%) used symptomatic medications for Alzheimer disease. 2 key findings →
Design: clinical trial Participants: 1,087 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The drug did not prevent clinical progression in a trial involving patients with mild-to-moderate dementia due to Alzheimer's disease. 4 key findings →
Participants: 1,454 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Selection criteria All unconfounded, double-blind, randomized controlled trials in which treatment with donepezil was compared with placebo for patients with mild, moderate or severe dementia due to Alzheimer's disease. 5 key findings →
Participants: 5,272 Evidence: high
Full summary, score breakdown and related studies → Original source
In this clinical trial, older adults with MCI receiving aerobic-resistance exercises with sequential computerized cognitive training significantly improved cognition, although some results were inconsistent. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
We aimed to evaluate the feasibility of multidomain intervention (MI) tailored to the Korean context. 1 key finding →
Design: randomized controlled trial Participants: 51 Evidence: high
Full summary, score breakdown and related studies → Original source
The AgeWell.de intervention reduced dementia risk. 1 key finding →
Participants: 461 Evidence: low
Full summary, score breakdown and related studies → Original source
There was no significant reduction in hospital transfers per 1000 person-days alive in the intervention vs control groups (rate [SE], 3.7 [0.2]; 95% CI, 3.4-4.0 vs 3.9 [0.3]; 95% CI, 3.6-4.1; rate difference [SE], -0.2 [0.3]; 95% CI, -0.5 to 0.2). 3 key findings →
Participants: 4,171 Evidence: high
Full summary, score breakdown and related studies → Original source
Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and symptomatic stages to delay or slow disease progression. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the clinical deterioration of Alzheimer’s disease (AD). 2 key findings →
Design: systematic review Participants: 396 Evidence: high
Full summary, score breakdown and related studies → Original source
The safety profile of aducanumab remained unchanged in the LTE of PRIME. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
8 of the 1,863 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →